Please assess the completion status of the following clinical trial:

Trial Title: Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* Age 18 or older~* HIV plasma viral load \<50 copies/ml for at least 3 years with at least one measurement per year and most recent viral load within 3 months of screening.~* Receiving combination antiretroviral therapy (at least 3 agents); subjects must be on a efavirenz-based or a ritonavir-based regimen~* Two CD4+ T cell counts greater than 350 cell/µl in the six months prior to screening~* Willing to abstain from any alcohol one day before, during the three day period in which disulfiram will be administered and the two week period immediately after disulfiram administration~Exclusion Criteria:~* Current alcohol use disorder or hazardous alcohol use~* Current use of any drug formulation that contains alcohol or that might contain alcohol, including the gelatin capsule and liquid formulations of ritonavir, ritonavir/lopinavir, amprenavir and fosamprenavir.~* Current use of tipranavir or maraviroc.~* Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has potent irreversible inhibitory effects on mitochondrial metabolism and hence could exacerbate the toxicity of these drugs).~* Concurrent use of rivaroxaban ( a CYP3A metabolized medication) as the cytochrome P450 inhibitory effects of disulfiram on rivaroxaban are unknown.~* Current use of warfarin~* Patients who are intending to modify antiretroviral therapy in the next 2 weeks for any reason.~* Serious illness requiring hospitalization or parental antibiotics within preceding 3 months~* A screening hemoglobin below 12.5 g/dL~* A screening TSH consistent with Hypothyroidism~* Significant renal disease or acute nephritis~* Significant myocardial disease or diagnosed coronary artery disease~* Significant respiratory disease~* History of psychosis, seizure disorder, abnormal electroencephalogram or brain damage with significant persisting neurological deficit.~* Clinically active hepatitis as evidenced by clinical jaundice or Grade 2 or higher liver function test abnormalities.~* Hepatic cirrhosis or decompensated chronic liver disease.~* Diabetes or current hypothyroidism.~* Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in past 16 weeks.~* Recent exposure (within the preceding 8 weeks) to any vaccine.~* Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.~* Significant substance use, which in the opinion of the investigator, is likely to interfere with the conduct of the study.~* Prior or current use of disulfiram, vorinostat or other experimental agent used with the intent to perturb the HIV-1 viral reservoir~* Current use of an antiretroviral regimen which does not include either efavirenz or a protease inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- disulfiram 500mg (Type: EXPERIMENTAL): 500mg disulfiram by mouth per day for 3 days
- disulfiram 1000mg (Type: EXPERIMENTAL): 1000mg disulfiram by mouth per day for 3 days
- disulfiram 2000mg (Type: EXPERIMENTAL): 2000mg disulfiram per mouth per day for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete